Trials On World’s First Viable Blood Substitute Aimed For India, U.S.
This article was originally published in PharmAsia News
The first trials outside the United States for a HemoBioTech's blood substitute are planned for India where Phase I trials could begin this year. HemoBioTech said California-based Paragon Biomedical, which has an office in India, is to run the trials in both countries on the HemoTech artificial blood product and has applied for permission to run the clinical trials on what would be the world's first viable blood substitute. HemoBioTech hopes to test the product on patients with acute anemia, those requiring angioplasty and on trauma patients. (Click here for more
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.